-
1Academic JournalNeuromyelitis optica spectrum disorders in children ; Заболевания спектра оптиконевромиелита у детей
المؤلفون: N. F. Akhmetgaleeva, T. O. Simaniv, E. M. Yausheva, Yа. A. Saitova, O. V. Lyutov, M. A. Kutlubaev, K. Z. Bakhtiyarova, Н. Ф. Ахметгалеева, Т. О. Симанив, Э. М. Яушева, Я. А. Саитова, О. В. Лютов, М. А. Кутлубаев, К. З. Бахтиярова
المساهمون: The investigation has not been sponsored, Исследование не имело спонсорской поддержки
المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 16 (2024): (Suppl. 2); 65-73 ; Неврология, нейропсихиатрия, психосоматика; Vol 16 (2024): (Suppl. 2); 65-73 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-0
مصطلحات موضوعية: лечение, neuromyelitis optica spectrum diseases, aquaporin-4, paediatric patients, differential diagnosis, treatment, заболевания спектра оптиконевромиелита, аквапорин-4, дети, дифференциальная диагностика
وصف الملف: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2318/1692; Jarius S, Aktas O, Ayzenberg I, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-68. doi:10.1007/s00415-023-11634-0. Epub 2023 Apr 6.; Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to WorkUp and Diagnosis. Front Pediatr. 2020 Jun 25;8:339. doi:10.3389/fped.2020.00339. Erratum in: Front Pediatr. 2021 Feb 15;8:642203. doi:10.3389/fped.2020.642203; Хайбуллин ТН, Кириллова ЕВ, Бикбаев РМ и др. Клинико-эпидемиологические характеристики рассеянного склероза и оптиконейромиелита в Центральной Азии. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(2-2):12-7. doi:10.17116/jnevro20191192212; Papp V, Magyari M, Aktas O, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2021 Jan 12;96(2):59-77. doi:10.1212/WNL.0000000000011153. Epub 2020 Dec 11.; Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi:10.3389/fneur.2020.00501; Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016 Jan 19;86(3):245-52. doi:10.1212/WNL.0000000000002283. Epub 2015 Dec 18.; Fragoso YD, Ferreira ML, Oliveira EM, et al. Neuromyelitis optica with onset in childhood and adolescence. Pediatr Neurol. 2014 Jan;50(1):66-8. doi:10.1016/j.pediatrneurol.2013.07.003. Epub 2013 Oct 13.; Стародубов ВИ, Зеленова ОВ, Абрамов СИ и др. Первое обсервационное эпидемиологическое исследование по определению заболеваемости и распространенности заболеваний спектра оптиконевромиелита (оптиконевромиелит, болезнь Девика) на территории Российской Федерации. Современные проблемы здравоохранения и медицинской статистики. 2021;(1):130-41. doi:10.24411/2312-2935-2021-00007; Луцик ВН, Котов АС, Борисова МН и др. Оптикомиелит Девика у ребенка. Неврологический журнал. 2017;22 (4):205-10. doi:10.18821/1560-9545-2017-22-4-205-210; Котов АС, Токарева ЮВ, Луцик ВН и др. Расстройство изспектра оптиконевромиелита в детском возрасте (клинический случай). Русский журнал детской неврологии. 2017;(4):56-62. doi:10.17650/2073-8803-2017-12-4-56-62; Токарева ЮВ, Котов АС, Пантелеева МВ и др. Расстройства из спектра оптиконевромиелита у пациентов детского возраста. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):60-4. doi:10.14412/2074-2711-2018-1-60-64; Abe Y, Yasui M. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System. Biomolecules. 2022 Apr 17;12(4):591. doi:10.3390/biom12040591; Зайцева ПА, Бойко АН. Заболевания спектра оптиконевромиелита: от патогенеза к таргетной терапии. Неврология, нейропсихиатрия, психосоматика. 2023;15(Прил. 1):49-57. doi:10.14412/2074-2711-2023-1S-49-57; Trebst C, Jarius S, Berthele A, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014 Jan;261(1):1-16. doi:10.1007/s00415-013-7169-7. Epub 2013 Nov 23.; Cazzaniga J, Jara Silva CE, Quinonez J, et al. Neuromyelitis Optica Spectrum Disorder. Cureus. 2023 Nov 2;15(11):e48168. doi:10.7759/cureus.48168; Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023 Sep 28;14:1255533. doi:10.3389/fimmu.2023.1255533; Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 20;7(5):e841. doi:10.1212/NXI.0000000000000841; Симанив ТО, Бахтиярова КЗ, Белова АН и др. Заболевания спектра оптиконевромиелита (ЗСОНМ) – диагностические критерии и подходы к терапии. Неврология, нейропсихиатрия, психосоматика. 2023;15(Прил. 1):71-5. doi:10.14412/2074-2711-2023-1S-71-75; Yan Y, Li Y, Fu Y, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016 Dec;59(12):1270-81. doi:10.1007/s11427-015-4997-y. Epub 2016 Feb 26.; Bruijstens AL, Lechner C, Flet-Berliac L, et al. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13. doi:10.1016/j.ejpn.2020.10.006. Epub 2020 Nov 4.; Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi:10.1212/WNL.0000000000001729. Epub 2015 Jun 19.; Белова АН, Бойко АН, Белова ЕМ. Диагностические критерии оптикомиелит- ассоциированных расстройств. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2016;116(2-2):32-40. doi:10.17116/jnevro20161162232-40; Baghbanian SM, Asgari N, Sahraian MA, Moghadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018 May 15;388:222-31. doi:10.1016/j.jns.2018.02.028. Epub 2018 Feb 19.; Paolilo RB, Hacohen Y, Yazbeck E, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 30;7(5):e837. doi:10.1212/NXI.0000000000000837; Camera V, Messina S, Elhadd KT, et al. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):101-11. doi:10.1136/jnnp-2021-327206. Epub 2021 Sep 28.; Hacohen Y, Messina S, Gan HW, et al. Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. Mult Scler. 2018 Apr;24(5):679-84. doi:10.1177/1352458517726593. Epub 2017 Aug 14.; Kim HJ, Paul F, Lana-Peixoto MA, et al; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. doi:10.1212/WNL.0000000000001367. Epub 2015 Feb 18.; Bourre B, Zephir H, Ongagna JC, et al. Long-term follow-up of acute partial transverse; Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014 May;20(6):695-704. doi:10.1177/1352458513506953. Epub 2013 Sep 26.; Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72. doi:10.1136/jnnp-2014-308346. Epub 2014 Aug 13.; Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485-9. doi:10.1212/01.wnl.0000216139.44259.74; Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013 Apr 2;80(14):1330-7. doi:10.1212/WNL.0b013e3182887957. Epub 2013 Mar 13.; Mader S, Obholzer B, Reindl M. Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights. InTech. 2011. doi:10.5772/20517; Yin HX, Wang YJ, Liu MG, et al. Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants. Ann Neurol. 2023 Jun;93(6):1069-81. doi:10.1002/ana.26623. Epub 2023 Mar 13.; Poisson K, Moeller K, Fisher KS. Pediatric Neuromyelitis Optica Spectrum Disorder. Semin Pediatr Neurol. 2023 Jul;46:101051. doi:10.1016/j.spen.2023.101051. Epub 2023 Apr 30.; Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019 Jan;27:350-63. doi:10.1016/j.msard.2018.11.008. Epub 2018 Nov 16.; Mealy MA, Kozachik SL, Levy M. Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Manag Nurs. 2019 Dec;20(6):580-91. doi:10.1016/j.pmn.2019.03.003. Epub 2019 May 15.; Ferilli MAN, Paparella R, Morandini I, et al. Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life (Basel). 2021 Dec 23;12(1):19. doi:10.3390/life12010019 A systematic review and meta-analysis. J Neuroimmunol. 2020 Nov 20;350:577449. doi:10.1016/j.jneuroim.2020.577449. Epub ahead of print.; Li Z, Wan L, Liu X, et al. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. Front Immunol. 2023 Jan 5;13:1113406. doi:10.3389/fimmu.2022.1113406; Zhou Y, Zhong X, Shu Y, et al. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019 Feb;28:213-20. doi:10.1016/j.msard.2018.12.038. Epub 2019 Jan 3.; Paolilo RB, da Paz JA, Apostolos-Pereira SL, et al. Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort. Mult Scler Relat Disord. 2021 Nov;56:103252. doi:10.1016/j.msard.2021.103252. Epub 2021 Sep 10.; Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012 Oct;18(10):1480-3. doi:10.1177/1352458512439439. Epub 2012 Feb 21.; Ayzenberg I, Schöllhammer J, Hoepner R, et al; Neuromyelitis Optica Study Group. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retro- spective study. J Neurol. 2016 Mar;263(3):575-82. doi:10.1007/s00415-015-7991-1. Epub 2016 Jan 25.; Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 Jan;18(1):113-5. doi:10.1177/1352458511431973. Epub 2011 Dec 6.; Bonnan M, Berthelot E, Cabre P. Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation. Mult Scler Relat Disord. 2021 Jul;52:102975. doi:10.1016/j.msard.2021.102975. Epub 2021 Apr 24.; Gahlen A, Trampe AK, Haupeltshofer S, et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi:10.1212/NXI.0000000000000363; Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016 Jan;263(1):25-9. doi:10.1007/s00415-015-7925-y; Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. myelitis. Arch Neurol. 2012 Mar;69(3):357-62. doi:10.1001/archneurol.2011.949. Erratum in: Arch Neurol. 2012 Jun;69(6):789.; Yu HH, Qin C, Zhang SQ, et al. Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: Mult Scler. 2017 Aug;23(9):1297-300. doi:10.1177/1352458517694086. Epub 2017 Apr 10.; Прахова ЛН, Краснов ВС, Касаткин ДС и др. Локальный опыт применения препарата сатрализумаб, подавляющего путь IL-6, для терапии заболеваний спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2022;122(7-2):68-72. doi:10.17116/jnevro202212207268; Heo YA. Satralizumab: First Approval. Drugs. 2020 Sep;80(14):1477-82. doi:10.1007/s40265-020-01380-2. Erratum in: Drugs. 2020 Sep;80(14):1483. doi:10.1007/s40265-020-01391-z; Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi:10.1056/NEJMoa1901747; Li X, Wu W, Zeng Y, et al. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report. Front Immunol. 2023 Oct 17;14:1257955. doi:10.3389/fimmu.2023.1257955; Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi:10.1056/NEJMoa1900866. Epub 2019 May 3.; Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 Jun;93(6):1053-68. doi:10.1002/ana.26626. Epub 2023 Apr 5.; Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика. 2017;16(1):51-4.; Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8;83(2):142-50. doi:10.1212/WNL.0000000000000570. Epub 2014 Jun 11.; Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e188. doi:10.1212/NXI.0000000000000188; Deya-Martinez A, Gordon Y, Molina-Anguita C, et al. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm. 2020 May 6;7(4):e724. doi:10.1212/NXI.0000000000000724; Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019 Aug;33:22-32. doi:10.1016/j.msard.2019.05.011. Epub 2019 May 22.; https://nnp.ima-press.net/nnp/article/view/2318
-
2Academic Journal
المؤلفون: T. O. Simaniv, K. Z. Bakhtiyarova, A. N. Belova, Z. A. Goncharova, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, T. N. Trushnikova, E. L. Turova, T. I. Khaibullin, M. A. Sherman, A. N. Boyko, Т. О. Симанив, К. З. Бахтиярова, А. Н. Белова, З. А. Гончарова, С. А. Сиверцева, Н. Н. Спирин, Н. А. Тотолян, Т. Н. Трушникова, Е. Л. Турова, Т. И. Хайбуллин, М. А. Шерман, А. Н. Бойко
المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15 (2023): (Suppl. 1); 71-75 ; Неврология, нейропсихиатрия, психосоматика; Vol 15 (2023): (Suppl. 1); 71-75 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-0
مصطلحات موضوعية: ингибиторы С5-компонента комплемента, diagnostics, therapy, Complement C5 inhibitors, диагностика, терапия
وصف الملف: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2082/1578; Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep;6(9):805-15. doi:10.1016/S1474-4422(07)70216-8; Borisow N, Mori M, Kuwabara S, et al. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018 Oct 23;9:888. doi:10.3389/fneur.2018.00888; Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi:10.3389/fneur.2020.00501; Шерман МА, Бойко АН. Эпидемиология заболеваний спектра оптиконевромиелита. Журнал неврологии и психиатрии им. С.С. Корса-кова. 2021;21(7-2):5-12. doi:10.17116/jnevro20211210725; Симанив ТО, Васильев АВ, Аскарова ЛШ, Захарова МН. Оптиконейромиелит и заболевания спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10-2):35-48. doi: 10/17116/jnevro20191191035; Стародубов ВИ, Зеленова ОВ, Абрамов СИ и др. Первое обсервационное эпидемиологическое исследование по определению заболеваемости и распространенности заболеваний спектра оптиконевромиелита (оптиконевромиелит, болезнь Девика) на территории Российской Федерации. Современные проблемы здравоохранения и медицинской статистики. 2021;(1):130-41. doi:10.24411/2312-2935-2021-00007; Pandit L, Asgari N, Apiwattanakul M, et al.; GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler. 2015 Jun;21(7):845-53. doi:10.1177/1352458515572406. Epub 2015 Apr 28.; Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol. 2008;318:343-56. doi:10.1007/978-3-540-73677-6_14; Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17;364(9451):2106-12. doi:10.1016/S0140-6736(04)17551-X; Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9:14. doi:10.1186/1742-2094-9-14; Wingerchuk DM, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. doi:10.1212/WNL.0000000000001729; Kim W, Lee JE, Li XF, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler. 2011;18(5):578-86. doi:10.1177/1352458511424590; Whittam D, Wilson M, Hamid S, et al. What's new in neuromyelitis optica? A short review for clinical neurologist. J Neurol. 2017;264(11):2330-44. doi:10.1007/s00415-017-8445-8; Waters P, Pittock SJ, Bennett JL, et al. Evaluation of aquaporine-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290-303. doi:10.1111/cen3.12107; Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-82. doi:10.1016/S1474-4422(22)00431-8; Tajfirouz DA, Bhatti MT, Chen JJ. Clinical Characteristics and Treatment of MOG-IgGAssociated Optic Neuritis. Curr Neurol Neurosci Rep. 2019;19:100. doi:10.1007/s11910-019-1014-z; Kunchok A, Chen JJ, McKeon A, et al. Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. JAMA Neurol. 2020;77:257-9. doi:10.1001/jamaneurol.2019.3656; Liu C, Shi M, Zhu M, et al. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges. Autoimmun Rev. 2022 Jan;21(1):102921. doi:10.1016/j.autrev.2021.102921. Epub 2021 Aug 10.; Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012 Feb 28;78(9):665-71; discussion 669. doi:10.1212/WNL.0b013e318248dec1. Epub 2012 Feb 1.; Краснов ВС, Тотолян НА, Назаров ВД и др. Актуальные вопросы диагностики заболеваний спектра оптиконейромиелита при определении антител к аквапорину-4 в сыворотке крови. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7-2):24-31. doi:10.17116/jnevro202012007224; Кротенкова МВ, Брюхов ВВ, Морозова СН, Кротенкова ИА. Магнитно-резонансная томография в диагностике и дифференциальной диагностике рассеянного склероза. Руководство для врачей. Москва: ГЭОТАР-Медиа; 2019. 160 с.; Симанив ТО, Краснов ВС, Касаткин ДС. Оптиконевромиелит в фокусе. Практическое руководство в схемах и таблицах. Москва: Практическая медицина; 2023. 176 с.; Белов СЕ, Бойко АН. Симптом центральной вены при разных заболеваниях и протоколах МР-исследования и значениях поля томографа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(7-2):19-26. doi:10.17116/jnevro202212207219; Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):137-45. doi:10.1136/jnnp-2016-313300. Epub 2016 Sep 26; Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003 Mar 11;60(5):848-53. doi:10.1212/01.wnl.0000049912.02954.2c; Ma X, Kermode AG, Hu X, Qiu W. Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy. Mult Scler Relat Disord. 2020 Nov;46:102522. doi:10.1016/j.msard.2020.102522. Epub 2020 Sep 19.; Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019 May 1;142(5):1310-23. doi:10.1093/brain/awz054; Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. doi:10.1212/wnl.33.11.1444; Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020 Nov 15;348:577387. doi:10.1016/j.jneuroim.2020.577387. Epub 2020 Sep 8.; Schwartz CE, Stark RB, Stucky BD. Response-shift effects in neuromyelitis optica spectrum disorder: a secondary analysis of clinical trial data. Qual Life Res. 2021 May;30(5):1267-82. doi:10.1007/s11136-020-02707-y. Epub 2020 Dec 2.; Pittock SJ, Fujihara K, Palace J, et al; PREVENT Study Group. Eculizumab monotherapy for NMOSD: Data from PREVENT and its openlabel extension. Mult Scler. 2022 Mar;28(3):480-6. doi:10.1177/13524585211038291. Epub 2021 Sep 9.; Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346-51. doi:10.1136/jnnp-2017-316286. Epub 2017 Oct 13.; Mealy MA, Mossburg SE, Kim SH, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019 Feb;28:64-8. doi:10.1016/j.msard.2018.12.011. Epub 2018 Dec 9.; Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice Mult Scler Relat Disord. 2020 Oct;45:102428. Mult Scler Relat Disord. 2021 Jul;52:103026. doi:10.1016/j.msard.2021.103026. Epub 2021 May 25. Erratum for: Mult Scler Relat Disord. 2020 Oct;45:102428.; Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021 Jan;20(1):60-7. doi:10.1016/S1474-4422(20)30392-6. Epub 2020 Nov 10.; Ciron J, Audoin B, Bourre B, et al; NOMADMUS group, under the aegis of OFSEP, SFSEP. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018 Apr;174(4):255-64. doi:10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30.; Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019 Mar 6;19(1):36. doi:10.1186/s12883-019-1261-2; Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017 Sep;264(9):2003-9. doi:10.1007/s00415-017-8590-0. Epub 2017 Aug 22.; Songwisit S, Kosiyakul P, Jitprapaikulsan J, et al. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020 Oct 7;10(1):16727. doi:10.1038/s41598-020-73882-8; Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015 Jul;72(7):756-63. doi:10.1001/jamaneurol. 2015.0533; Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi:10.1056/NEJMoa1901747; Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-12. doi:10.1016/S1474-4422(20)30078-8; Nytrova P, Potlukova E, Kemlink D, et al. Complement activation in patients with neuromyelitis optica. J Neuroimmunol. 2014 Sep 15;274(1-2):185-91. doi:10.1016/j.jneuroim. 2014.07.001. Epub 2014 Jul 11.; Saadoun S, Papadopoulos MC. Role of membrane complement regulators in neuromyelitis optica. Mult Scler. 2015 Nov;21(13):1644-54. doi:10.1177/1352458515571446. Epub 2015 Feb 19.; Saadoun S, Waters P, Bell BA, et al. Intracerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010 Feb;133(Pt 2):349-61. doi:10.1093/brain/awp309. Epub 2010 Jan 4.; Kuroda H, Fujihara K, Takano R, et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2013 Jan 15;254(1-2):178-82. doi:10.1016/j.jneuroim.2012.09.002. Epub 2012 Sep 25.; Wang H, Wang K, Wang C, et al. Increased soluble C5b-9 in CSF of neuromyelitis optica. Scand J Immunol. 2014 Feb;79(2):127-30. doi:10.1111/sji.12132; Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi:10.1056/NEJMoa1900866; Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD). Published 10 May 2023. Available at: https://www.astrazeneca.com/media-centre/pressreleases/2023/ultomiris-approved-in-the-eu-foradults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html (accessed 03.07.2023).; Ariceta G, Dixon BP, Kim SH, et al; 312 Study Group. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naХve to complement inhibitor treatment. Kidney Int. 2021 Jul;100(1):225-37. doi:10.1016/j.kint.2020.10.046. Epub 2020 Dec 8.; Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 Jun;93(6):1053-68. doi:10.1002/ana.26626; https://nnp.ima-press.net/nnp/article/view/2082
-
3Academic Journal
المؤلفون: A. O. Kozlova, D. D. Eliseeva, T. O. Simaniv, V. V. Bryukhov, E. V. Baidina, M. N. Zakharova, А. О. Козлова, Д. Д. Елисеева, Т. О. Симанив, В. В. Брюхов, Е. В. Байдина, М. Н. Захарова
المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз; 21-28 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз; 21-28 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-1S
مصطلحات موضوعية: миелит, autoimmune lesions, spinal cord, myelitis, аутоиммунные поражения, спинной мозг
وصف الملف: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1849/1426; Al-Salihi KA, Khalaf JM. The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects. Vet World. 2021 Jan;14(1):190-9. doi:10.14202/ vetworld.2021.190-199. Epub 2021 Jan 23.; Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15; 395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.; Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):819-824. doi:10.1001/jamacardio.2020.1096; Zoghi G, Moosavy SH, Yavarian S, et al. Gastrointestinal implications in COVID-19. BMC Infect Dis. 2021 Nov 4;21(1):1135. doi:10.1186/s12879-021-06824-y; Gomez-Mesa JE, Galindo-Coral S, Montes MC, Munoz Martin AJ. Thrombosis and Coagulopathy in COVID-19. Curr Probl Cardiol. 2021 Mar;46(3):100742. doi:10.1016/j.cpcardiol.2020.100742. Epub 2020 Nov 2.; Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci. 2020 May;98(2):75-81. doi:10.1016/j.jdermsci.2020.04.011. Epub 2020 Apr 29.; Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020 Apr 2;28(3):391-5. doi:10.1080/09273948.2020.1738501. Epub 2020 Mar 16.; Espindola OM, Gomes YCP, Brandao CO, et al. Inflammatory Cytokine Patterns Associated with Neurological Diseases in Coronavirus Disease 2019. Ann Neurol. 2021 May;89(5):1041-5. doi:10.1002/ana.26041. Epub 2021 Feb 24.; Bernard-Valnet R, Perriot S, Canales M, et al. Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation. Neurol Neuroimmunol Neuroinflamm. 2021 Jun 16;8(5):e1029. doi:10.1212/NXI.0000000000001029; Moody R, Wilson K, Flanagan KL, et al. Adaptive Immunity and the Risk of Autoreactivity in COVID-19. Int J Mol Sci. 2021 Aug 20;22(16):8965. doi:10.3390/ijms22168965; Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18): 1708-20. doi:10.1056/NEJMoa2002032. Epub 2020 Feb 28.; Chou SH-Y, Beghi E, Helbok R, et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19 – A Report for the GCSNeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. 2021 May 3; 4(5):e2112131. doi:10.1001/jamanetworkopen.2021.12131; Rifino N, Censori B, Agazzi E, et al. Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol. 2021 Jul; 268(7):2331-8. doi:10.1007/s00415-020-10251-5. Epub 2020 Oct 7.; Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022 Feb;23(2):194-202. doi:10.1038/s41590-021-01104-y. Epub 2022 Feb 1.; Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. BioRxiv Prepr Serv Biol. 2020. doi:10.1101/2020.06.25.169946; Sanclemente-Alaman I, MorenoJimenez L, Benito-Martin MS, et al. Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. Front Immunol. 2020 Aug 28;11:2163. doi:10.3389/fimmu.2020.02163.eCollection 2020.; Гусев ЕИ, Мартынов МЮ, Бойко АН и др. Новая коронавирусная инфекция (COVID-19) и поражение нервной системы: механизмы неврологических расстройств, клинические проявления, организация неврологической помощи. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(6):7-16. doi:10.17116/jnevro20201200617 [Gusev EI, Martynov MYu, Boyko AN, et al. Novel coronavirus infection (COVID-19) and nervous system involvement: pathogenesis, clinical manifestations, organization of neurological care. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2020;120(6):7-16. doi:10.17116/jnevro20201200617 (In Russ.)].; Hu J, Jolkkonen J, Zhao C. Neurotropism of SARS-CoV-2 and its neuropathological alterations: Similarities with other coronaviruses. Neurosci Biobehav Rev. 2020 Dec;119: 184-93. doi:10.1016/j.neubiorev.2020.10.012. Epub 2020 Oct 19.; Blackburn KM, Wang C. Post-infectious neurological disorders. Ther Adv Neurol Disord. 2020 Aug 30;13:1756286420952901. doi:10.1177/1756286420952901. eCollection 2020.; Zhao K, Huang J, Dai D, et al. Acute myelitis after SARS-CoV-2 infection: a case report. MedRxiv. 2020:2020.03.16.20035105. doi:10.1101/2020.03.16.20035105; Saberi A, Ghayeghran A, Hatamian H, et al. COVID-19-associated Myelitis, Para/Po Infectious or Infectious Myelitis. J Neurol Sci. 2020;6:21. doi:10.32598/CJNS.6.21.1; Sarma D, Bilello LA. A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection. Clin Pract Cases Emerg Med. 2020 Aug;4(3):321-3. doi:10.5811/cpcem.2020.5.47937; Novi G, Rossi T, Pedemonte E, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 1;7(5):e797. doi:10.1212/NXI.0000000000000797. Print 2020 Sep.; Abdelhady M, Elsotouhy A, Vattoth S. Acute Flaccid Myelitis in COVID-19. BJR Case Rep. 2020 Jul 24;6(3):20200098. doi:10.1259/bjrcr.20200098; Sotoca J, Rodriguez-Alvarez Y. COVID-19- associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 10; 7(5):e803. doi:10.1212/NXI.0000000000000803. Print 2020 Sep.; Zanin L, Saraceno G, Panciani PP, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 2020 Jul;162(7):1491-4. doi:10.1007/s00701-020-04374-x. Epub 2020 May 4.; Huang HY, Shah LM, McNally JS, et al. COVID-19-Associated Myelitis Involving the Dorsal and Lateral White Matter Tracts: A Case Series and Review of the Literature. AJNR Am J Neuroradiol. 2021 Oct;42(10):1912-7. doi:10.3174/ajnr.A7256. Epub 2021 Aug 19.; Sampogna G, Tessitore N, Bianconi T, et al. Spinal cord dysfunction after COVID-19 infection. Spinal Cord Ser Cases. 2020 Sep 30;6(1): 92. doi:10.1038/s41394-020-00341-x; Shaw VC, Chander G, Puttanna A. Neuromyelitis optica spectrum disorder secondary to COVID-19. Br J Hosp Med. 2020 Sep 2; 81(9):1-3. doi:10.12968/hmed.2020.0401. Epub 2020 Sep 5.; Batum M, Kisabay Ak A, Mavioglu H. COVID-19 infection-induced neuromyelitis optica: a case report. Int J Neurosci. 2020 Dec 30; 1-7. doi:10.1080/00207454.2020.1860036. Online ahead of print.; Zhou S, Jones-Lopez EC, Soneji DJ, Azevedo CJ, Patel VR. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19. J Neuroophthalmol. 2020 Sep;40(3):398-402. doi:10.1097/WNO.0000000000001049; Garg RK, Paliwal VK, Gupta A. Spinal cord involvement in COVID-19: A review. J Spinal Cord Med. 2021 Mar 11;1-15. doi:10.1080/10790268.2021.1888022. Online ahead of print.; West TW, Hess C, Cree BAC. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012 Apr;32(2):97-113. doi:10.1055/s-0032-1322586. Epub 2012 Sep 8.; Marx A, Glass JD, Sutter RW. Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev. 2000;22(2):298-316. doi:10.1093/oxfordjournals.epirev.a018041; Roman GC, Gracia F, Torres A, et al. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol. 2021 Apr 26;12: 653786. doi:10.3389/fimmu.2021.653786. eCollection 2021.; Ахмеджанова ЛТ, Воскресенская ОН, Исайкин АИ и др. Острый рассеянный энцефаломиелит и миелит на фоне новой коронавирусной инфекции COVID-19. Клиническое наблюдение. Терапевтический архив. 2021;93(11):1375-80. doi:10.26442/00403660.2021.11.201168 [Akhmedzhanova LT, Voskresenskaia ON, Isaikin AI, et al. Acute disseminated encephalomyelitis and myelitis associated with new coronavirus infection COVID-19. Case report. Terapevticheskii arkhiv. 2021;93:1375-80. doi:10.26442/00403660.2021.11.201168 (In Russ.)].; Royston M, Kielhorn A, Weycker D, et al. Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice. Neurol Ther. 2021 Dec;10(2):767-83. doi:10.1007/s40120-021-00253-4. Epub 2021 May 27.; Epstein SE, Levin S, Onomichi K, et al. Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses. Mult Scler Relat Disord. 2021 Nov;56:103229. doi:10.1016/j.msard. 2021.103229. Epub 2021 Aug 28.; Kranz PG, Amrhein TJ. Imaging Approach to Myelopathy: Acute, Subacute, and Chronic. Radiol Clin North Am. 2019;57:257-79. doi:10.1016/j.rcl.2018.09.006; Umehara F, Nose H, Saito M, et al. Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy. J Neurovirol. 2007 Jun;13(3): 260-7. doi:10.1080/13550280701258431; Cobo-Calvo A, Sepulveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflamm. 2019 Jul 2;16(1):134. doi:10.1186/s12974-019-1525-1; https://nnp.ima-press.net/nnp/article/view/1849